<DOC>
	<DOC>NCT00786448</DOC>
	<brief_summary>- Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.</brief_summary>
	<brief_title>Post Marketing Surveillance Study on Emselex After Launch in Germany</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Patients who are treated with Emselex for Overactive Bladder Exclusion criteria are the contraindications as specified in the German product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>